Identification of novel neutralizing determinants for protection against HCV

Autor: Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein

Publikováno v: Alzua, G P, Pihl, A F, Offersgaard, A, Velázquez-Moctezuma, R, Duarte Hernandez, C R, Augestad, E H, Fahnøe, U, Mathiesen, C K, Krarup, H, Law, M, Prentoe, J, Bukh, J & Gottwein, J M 2023, ' Identification of novel neutralizing determinants for protection against HCV ', Hepatology, vol. 73, no. 3, pp. 982-996 . https://doi.org/10.1002/hep.32772
Alzua, G P, Pihl, A F, Offersgaard, A, Velázquez-Moctezuma, R, Hernandez, C R D, Augestad, E H, Fahnøe, U, Mathiesen, C K, Krarup, H, Law, M, Prentoe, J, Bukh, J & Gottwein, J M 2023, ' Identification of novel neutralizing determinants for protection against HCV ', Hepatology, vol. 77, no. 3, pp. 982-996 . https://doi.org/10.1002/hep.32772

BACKGROUND AND AIMS: HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine. N-linked glycosylation of viral envelope proteins is a key mechanism for such evasio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee8ddda5099418631770b24f323c860
https://curis.ku.dk/portal/da/publications/identification-of-novel-neutralizing-determinants-for-protection-against-hcv(8ae9404e-763e-4513-aa0e-d6bc1800cc97).html

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

Autor: Keven, Lothert, Anna F, Offersgaard, Anne F, Pihl, Christian K, Mathiesen, Tanja B, Jensen, Garazi Peña, Alzua, Ulrik, Fahnøe, Jens, Bukh, Judith M, Gottwein, Michael W, Wolff

Publikováno v: Scientific reports. 10(1)

There is a large unmet need for a prophylactic hepatitis C virus (HCV) vaccine to control the ongoing epidemic with this deadly pathogen. Many antiviral vaccines employ whole viruses as antigens. For HCV, this approach became feasible following the d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::96ad9cc22fe20e8f339f7f781b1f7803
https://pubmed.ncbi.nlm.nih.gov/33004836

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals

Autor: Christian K. Mathiesen, Jens Bukh, Ulrik Fahnøe, Judith M. Gottwein, Anna Offersgaard, Anne Finne Pihl, Henrik Krarup, Jannick Prentoe

Publikováno v: Pihl, A F, Offersgaard, A F, Mathiesen, C K, Prentoe, J, Fahnøe, U, Krarup, H, Bukh, J & Gottwein, J M 2018, ' High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals ', Scientific Reports, vol. 8, no. 1, 17505 . https://doi.org/10.1038/s41598-018-35010-5
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports

Chronic hepatitis C virus (HCV) infection poses a serious global public health burden. Despite the recent development of effective treatments there is a large unmet need for a prophylactic vaccine. Further, antiviral resistance might compromise treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad30dfd27cbf1f1286647011aaec65e8
https://curis.ku.dk/ws/files/209829958/s41598_018_35010_5.pdf

Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6

Autor: Mansun Law, Jens Bukh, Henrik Krarup, Jannick Prentoe, Alfredo Nicosia, Tanja B. Jensen, Judith M. Gottwein, Christian K. Mathiesen

Publikováno v: Mathiesen, C K, Jensen, T B, Prentoe, J, Krarup, H, Nicosia, A, Law, M, Bukh, J & Gottwein, J M 2014, ' Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6 ', Virology, vol. 458-459, pp. 190-208 . https://doi.org/10.1016/j.virol.2014.03.021

Recently, cell culture systems producing hepatitis C virus particles (HCVcc) were developed. Establishment of serum-free culture conditions is expected to facilitate development of a whole-virus inactivated HCV vaccine. We describe generation of geno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b383410c43d47faa6ed5c9c8ef3d7b20
https://pubmed.ncbi.nlm.nih.gov/24928051